Archives of Medical Research
Volume 41, Issue 3 , Pages 154-161 , April 2010

In Vitro Modulation of Peroxisome Proliferator-activated Receptor-γ and Its Genes by C-Reactive Protein. Role of Atorvastatin

  • Nitin Mahajan
    • ,
  • Veena Dhawan

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Veena Dhawan, Associate Professor, Department of Experimental Medicine & Biotechnology, Research Block ‘B’, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012, India; Phone: 91-172-2747585 (Ext. 5235); FAX: 91-172-2744401

Received 30 December 2009 ,Accepted 10 March 2010.

References 

  1. Packard RS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54:24–38
  2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503–516
  3. Castrillo A, Tontonz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol. 2004;20:455–480
  4. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75:346–359
  5. Zelcer N, Tontonoz P. Liver X receptor as integrator of metabolic and inflammatory signalling. J Clin Invest. 2006;116:607–614
  6. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEJM. 2002;347:1557–1565
  7. Cermak J, Key NS, Bach RR. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513–520
  8. Williams TN, Zhang CX, Game BA. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc(gamma)RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004;24:61–66
  9. Abe N, Osanai T, Fujiwara T, et al. C-reactive protein-induced up-regulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci. 2006;78:1021–1028
  10. Nabata A, Kuroki M, Ueba H, et al. C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque. Atherosclerosis. 2008;196:129–135
  11. Mahajan N, Bahl A, Dhawan V. C-reactive protein (CRP) up-regulates the expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of Atorvastatin. Int J Cardiol. 2009;
  12. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87–96
  13. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129–1135
  14. Blum A, Shamburek R. Pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis doi:10.1016/j.atherosclerosis.2008.08.022
  15. Paoletti R, Bolego C, Cignarella A. Lipid and non-lipid effects of statins. Hand Exp Pharmacol. 2005;170:359–382
  16. Almuti K, Rimawi R, Spevack D, et al. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;109:7–15
  17. Ichida Y, Hasegawa G, Fukui M, et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology. 2006;76:34–39
  18. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002;51:58–62
  19. Kaul D, Baba MI. Genomic effect of vitamin ‘C’ and statins within human mononuclear cells involved in atherogenic process. Eur J Clin Nutr. 2005;59:978–981
  20. Centrillo A, Joseph SB, Marathon C, et al. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. JBC. 2003;278:10443–10449
  21. Sharma I, Dhawan V, Mahajan N, et al. In vitro effects of atorvastatin on LPS-induced gene expression in endometriotic stromal cells. Fertil Steril. 2009;
  22. Mahajan N, Dhawan V, Sharma G, et al. Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolemic hypertensive sera and modulatory effects of green tea polyphenols. J Hum Hypert. 2008;22:141–143
  23. Duval C, Chinetti G, Trottein F. The role of PPARs in atherosclerosis. Trends Mol Med. 2002;8:422–430
  24. Li AC, Palinski W. Peroxisome proliferator activated receptor. How their effects on macrophages can lead to the development of new drug therapy against atherosclerosis. Anal Rev Pharmacol Toxicol. 2006;46:1–39
  25. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator activated receptor in inflammation control. J Endocrinol. 2001;169:453–459
  26. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17:1019–1025
  27. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. PNAS. 1998;75:7614–7619
  28. Inoue H, Tadashi T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPAR-γ. J Biol Chem. 2000;275:28028–28032
  29. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently co-localizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386–1392
  30. Burke AP, Kolodgie D, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Bio. 2004;24:1266–1271
  31. Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease. J Biomed Sci. 2006;13:17–26
  32. Qiu G, Hill JS. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res. 2007;48:2112–2122
  33. Hu WL, Qian SB, Li JJ. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Cytokine. 2007;40:201–206
  34. Kibayashi E, Urakaze M, Kobashi C, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci. 2005;108:515–521
  35. Hiraoka M, Nitta N, Nagai M, et al. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase, but not ERK1/2-dependent pathway. Life Sci. 2004;75:1333–1341
  36. Masamura K, Oida K, Kanehara H. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512–517
  37. Cilla DD, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther. 1996;60:687–695
  38. Oktem M, Esinler I, Eroglu D, et al. High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod. 2007;22:1474–1480
  39. Degraeve F, Bolla M, Blaie S. Modulation of COX-2 Expression by statins in human aortic smooth muscle cells: involvement of geranylgeranylated proteins. JBC. 2001;276:46849–46855

PII: S0188-4409(10)00096-2

doi: 10.1016/j.arcmed.2010.04.005

Archives of Medical Research
Volume 41, Issue 3 , Pages 154-161 , April 2010

Article Tools

* Image Usage & Resolution